April 29, 2024- Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by Day One Biopharmaceuticals, as a limited network specialty pharmacy for OJEMDATM (tovorafenib) for the treatment of pediatric low-grade glioma (pLGG).
OJEMDA, granted Rare Pediatric Disease Designation and approved by the U.S. Food and Drug Administration (FDA) on April 23, 2024, is an oral, brain-penetrant, highly selective type II RAF kinase inhibitor for the treatment of pLGG. Although considered a slow-growing tumor, pLGGs press on surrounding parts of the brain, which affects its function.
For more information about the symptoms, diagnosis, and treatment of pLGG, please click here. For more information about OJEMDA, including full prescribing information, please click here.